Compare BioNano Genomics Inc (BNGO) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Wynn Resorts, Limited — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Wynn Resorts, Limited trades at $96.52 (market cap $9.95B). The key difference: Wynn Resorts, Limited is far larger — about 753.8× BioNano Genomics Inc's market cap, and Wynn Resorts, Limited pays a 1.04% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | WYNN | |
|---|---|---|
Market Cap | $13.20M | $9.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $133.34 |
52-Week Low | $1.09 | $94.78 |
Enterprise Value | $15.81M | $20.32B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Wynn Resorts (WYNN) trades at $97.13, down 2.65% today, amid bearish technical signals and recent earnings misses. The stock faces margin pressure despite revenue growth, with net income margin declining to 5.14% in 2025. Analyst consensus remains bullish with a $134.30 price target, though technical indicators show resistance near $99-$103. Recent news highlights Q2 2026 earnings anticipation and luxury segment strength.
Outlook: Long-term potential exists via luxury focus and Macau recovery, but near-term risks include debt load ($10.5B), competitive pressures, and volatile earnings. Investors should weigh high analyst optimism against technical weakness and margin trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
